Search the Newsreel

Can Enphase Energy (ENPH) Hold Its Premium After Manufacturing Push?

Enphase Energy's stock has declined significantly over five years but now trades near its intrinsic value and market multiples. The company's recent expansion into U.S. manufacturing for power electronics and AI data center infrastructure supports long-term cash flow expectations. While valuation models suggest the …

Empowered Funds LLC Buys 119,202 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR

Empowered Funds LLC significantly increased its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 661.6% in the first quarter, adding 119,202 shares to reach a total of 137,220 shares valued at $8.6 million. This move is part of a broader trend of institutional investment, with …

Diversified Trust Co. Trims Position in Parker-Hannifin Corporation $PH

Diversified Trust Co. significantly reduced its stake in Parker-Hannifin Corporation (NYSE:PH) by 63.4% in the second quarter, selling 3,465 shares and retaining 2,001 shares valued at $1.96 million. Despite this trimming by one institutional investor, other hedge funds increased their positions, and institutional investors …

IONS Stock Jumps 4% After-Hours — Goldman Sachs Lifts Price Target On Tryngolza Approval

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Consensus Rating of "Moderate Buy" from Analysts

NRx Pharmaceuticals (NASDAQ:NRXP) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $34.50. Despite this, the company recently missed its quarterly earnings and revenue estimates. Hedge funds and institutional investors hold 4.27% of the stock.

Bank of America Corp DE Boosts Stake in Kiniksa Pharmaceuticals International, plc $KNSA

Teleconferência de Resultados do 2º Trimestre de 2026 da Alpha Cognition (ACOG): Vendas do ZUNVEYL Subem 71%

Alpha Cognition (ACOG) reportou um crescimento de 71% nas vendas líquidas do ZUNVEYL no 2º trimestre de 2026, atingindo US$ 6 milhões, impulsionado pela demanda de 8.294 frascos. A empresa reduziu sua projeção de despesas operacionais para o ano fiscal de 2026 para US$ …

Connect Biopharma (NASDAQ:CNTB) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen has upgraded Connect Biopharma (NASDAQ:CNTB) from a "sell" to a "hold" rating, though the broader analyst consensus remains a "Moderate Buy" with an average price target of $7.43. The company recently reported a quarterly loss of $0.27 per share, outperforming expectations, …

Vertex (VRTX) Stock Looks Above Fair Value On Earnings Yet About Right Overall

Vertex Pharmaceuticals (VRTX) has seen strong multi-year performance, with a 158.2% return over the past five years, but its current valuation suggests it's neither a clear bargain nor obviously overvalued. The stock trades at 29.1x earnings, slightly above Simply Wall St's fair P/E estimate …

Cathie Wood’s ARK Invest Loads Up On CRWV, GOOGL Stocks Before Mega Tech Earnings Day

Why Is CIFR Stock Rising Despite Q1 Earnings Miss?

Key facts: GOOG investment gains; Gemini 950M users; Waymo expands

Alphabet (GOOG) reported significant Q2 investment gains, making up about 10% of S&P 500 earnings, primarily from revaluation of equity stakes like SpaceX and Anthropic. Its AI model, Gemini, reached 950 million monthly users and is being integrated across Google products. Additionally, Waymo received …

Nouveau Monde Graphite (NYSE:NMG) Upgraded to Hold at Wall Street Zen

Wall Street Zen has upgraded Nouveau Monde Graphite (NYSE:NMG) from a "sell" to a "hold" rating. Despite this, MarketBeat indicates a consensus "Moderate Buy" rating with an average price target of $4.67 for the stock. NMG shares opened at $1.47, near their 52-week low, …

5-Day Rally Sends Phillips 66 Stock Up 15%

ARWR Stock Clocks Best Day In Nearly 8 Months As Analyst Lifts Price Target On Plozasiran Data

Alpha and Omega Semiconductor (AOSL) Stock May Be Undervalued Despite Q4 Loss Preview

Wall Street Zen Upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to Strong-Buy

Wall Street Zen has upgraded Regeneron Pharmaceuticals (NASDAQ:REGN) from a "buy" to a "strong-buy" rating. This upgrade follows Regeneron's strong quarterly earnings, where it surpassed analyst expectations for both EPS and revenue. Despite positive news regarding pipeline expansion and collaborations, the company faces risks …

Spheria Emerging Companies (ASX:SEC) Brings Small-Cap Exposure Into the August Dividend Calendar

NewAmsterdam Pharma (NAMS) Earnings Losses Raise The Question Of Whether The Stock Is A Bargain

Inovio Pharmaceuticals (NASDAQ:INO) Upgraded to "Hold" at Wall Street Zen

Wall Street Zen has upgraded Inovio Pharmaceuticals (NASDAQ:INO) from a "Sell" to a "Hold" rating, though overall analyst opinions remain mixed, with MarketBeat reporting a "Moderate Buy" consensus. The company recently exceeded earnings estimates, reporting a quarterly EPS of negative $0.07 against an expected …

Why Xeris Biopharma Holdings (XERS) Is Up 8.4% After Tightening 2026 Revenue Guidance And Advancing XP-8121

Eledon Pharmaceuticals (NASDAQ:ELDN) Upgraded at Wall Street Zen

Wall Street Zen upgraded Eledon Pharmaceuticals (NASDAQ:ELDN) from "strong sell" to "sell," though the broader analyst consensus remains "Hold" with a $9.67 target price. The company reported a quarterly loss of $0.27 per share, missing estimates, and its shares opened at $3.54. Institutional investors …

Oramed Pharmaceuticals (NASDAQ:ORMP) Upgraded by Wall Street Zen to Buy Rating

Wall Street Zen has upgraded Oramed Pharmaceuticals (NASDAQ:ORMP) from a "hold" to a "buy" rating, though MarketBeat's overall analyst rating for the company remains "Hold." Oramed Pharmaceuticals opened at $4.48, with a market capitalization of $186.35 million. The company recently reported a quarterly loss …

Roundhill GOOGL WeeklyPay ETF To Go Ex-Dividend On August 17th, 2026 With 0.39199 USD Dividend Per Share

The Roundhill GOOGL WeeklyPay ETF is set to go ex-dividend on August 17th, 2026. Shareholders will receive a dividend of 0.39199 USD per share.

NervGen Pharma (NASDAQ:NGEN) Stock Rating Lowered by Wall Street Zen

(PHIN) Volatility Zones as Tactical Triggers

Phinia Inc. (NASDAQ: PHIN) is showing weak near and mid-term sentiment, challenging its long-term positive outlook, with support currently being tested. An exceptional 38.0:1 risk-reward setup targets a 10.9% gain versus 0.3% risk. AI models have generated three distinct trading strategies—Position, Momentum Breakout, and …

LB Pharmaceuticals (NASDAQ:LBRX) Cut to Sell at Wall Street Zen

Wall Street Zen downgraded LB Pharmaceuticals (NASDAQ:LBRX) from "hold" to "sell" despite a broader analyst consensus of "Moderate Buy" with an average price target of $47.75. The company recently reported a quarterly loss of $1.71 per share, missing consensus estimates, and analysts anticipate a …

NRx Pharmaceuticals (NASDAQ:NRXP) Downgraded to "Sell" Rating by Wall Street Zen

Wall Street Zen has downgraded NRx Pharmaceuticals (NASDAQ:NRXP) from a "hold" to a "sell" rating, despite other analysts maintaining a "Moderate Buy" consensus with an average price target of $34.50. The company's stock opened at $3.27, reflecting a 2.1% drop, and recently reported a …

Wall Street Zen Upgrades Vor Biopharma (NASDAQ:VOR) to Hold

Wall Street Zen has upgraded Vor Biopharma (NASDAQ:VOR) from a "sell" to a "hold" rating. Despite this, the overall analyst consensus for Vor Biopharma remains a "Moderate Buy" with an average price target of $43.38, though the company's stock trades significantly below its 52-week …

Arbutus Biopharma (NASDAQ:ABUS) Cut to Hold at Wall Street Zen

Wall Street Zen downgraded Arbutus Biopharma (NASDAQ:ABUS) from a "buy" to a "hold" rating, though Weiss Ratings simultaneously upgraded it from "sell" to "hold." The biopharmaceutical company holds a consensus "Moderate Buy" rating and a $5.00 price target. Despite missing quarterly EPS estimates by …

Verrica Pharmaceuticals (NASDAQ:VRCA) Rating Lowered to Strong Sell at Wall Street Zen

Wall Street Zen downgraded Verrica Pharmaceuticals (NASDAQ:VRCA) from a "sell" to a "strong sell" rating. Despite this, the stock has a consensus "Hold" rating and an average target price of $14.50 from other analysts. The company recently reported a quarterly loss of $0.41 per …

Avalyn Pharma (NASDAQ:AVLN) Cut to Sell at Wall Street Zen

Wall Street Zen has downgraded Avalyn Pharma (NASDAQ:AVLN) from a "hold" to a "sell" rating, despite the overall analyst sentiment being a "Moderate Buy" with a $60 average price target. Other firms like Jefferies, Guggenheim, and Evercore have issued "buy" or "outperform" ratings, while …

How Investors May Respond To BioCryst (BCRX) Profit Swing, Raised Revenue Outlook And New ESOP Shares

BioCryst Pharmaceuticals reported a significant profit swing in Q2 2026, with revenue of US$218.25 million and net income of US$78.4 million, prompting a raised full-year revenue outlook to US$690 million–US$715 million. Despite this strong quarter, the company still faces a substantial year-to-date net loss …

Aarey Drugs & Pharmaceuticals standalone net profit declines 25.55% in the June 2026 quarter

(RIGL) Price Dynamics and Execution-Aware Positioning

This article analyzes Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) focusing on its price dynamics and execution-aware positioning based on AI models. It identifies strong near and mid-term sentiment, compelling upside potential due to a lack of resistance levels above the current price, and outlines specific …

Ascendis Pharma A/S (NASDAQ:ASND) Upgraded at Wall Street Zen

Wall Street Zen has upgraded Ascendis Pharma A/S (NASDAQ:ASND) from a "hold" to a "buy" rating, aligning with a consensus "Buy" rating and an average price target of $299.24 from other analysts. The company's shares opened 0.9% higher at $248.50, and it recently reported …